Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2: Results from a phase Ib clinical trial

European Journal of Cancer

Volumn 37, Issue 7, 2001, Pages 892-902

  Correale, P ^a   Campoccia, G ^a   Tsang, K Y ^b   Micheli, L ^a   Cusi, M G ^a   Sabatino, M ^a   Bruni, G ^a   Sestini, S ^a   Petrioli, R ^a   Pozzessere, D ^a   Marsili, S ^a   Fanetti, G ^a   Giorgi, G ^a   Francini, G ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antigen specific immunoreactivity; Dendritic cells; Hr GM CSF; Hr IL 2; Immunotherapy; Phase Ib clinical trial

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CARCINOMA; CELL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOCOMPETENCE; IMMUNOREACTIVITY; LYMPHOCYTE; MALE; MEMORY CELL; MONOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC DISEASE; TREATMENT OUTCOME;

AGED; ANTIGEN-ANTIBODY REACTIONS; ANTINEOPLASTIC AGENTS; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 0035049617     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00063-6     Document Type: Article

References (32)

1. Interleukin 2
2. Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies
3. The immunobiological effects of interleukin-2 in vivo
4. Immunotherapy for renal cell cancer
5. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens
6. Dendritic cells
7. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
8. An improved method for dendritic cell isolation with special regard to clinical applicability
9. Dendritic cells: A novel therapeutic modality
10. Granulocyte-macrophage colony stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro
11. Hematopoietic growth factors
12. Production of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony stimulating factor
13. Phase II trial of subcutaneously administered granulocyte-macrophage colony stimulating factor in patients with metastatic renal cell carcinoma
14. Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma
15. In vitro generation of prostate specific antigen (PSA) specific cytotoxic T-cell lines using recombinant vaccinia-PSA infected dendritic cells
16. The Staquet's, Sylvester's Cancer Clinical Trials: Methods and Practice
17. Autocrine feedback death and the regulation of mature T lymphocyte antigen receptors
18. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-γ
19. Design and analysis of randomized clinical trials requiring prolonged observations of each patients. II. Analysis and examples
20. Graphic representation of pain
21. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily
22. Clinical and immunological effects of granulocyte-macrophage colony stimulating factor coadministered with interleukin 2: A phase IB study
23. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony stimulating factor, low dose interleukin 2, and interferon a in progressive metastatic melanoma and renal cell carcinoma
24. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma
25. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmunary metastases
26. Biologic activity of low dosage IL-2 treatment in vivo
27. In vitro generation of human cytotoxic T lymphocytes for peptides derived from prostate-specific antigen
28. Immunotherapy update: From interleukin-2 to antigen specific therapy
29. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
30. Biological indices predictive of survival in 519 Italian terminally ill cancer patients
31. TH1 and TH2 cells: Different patterns of lymphokine section lead to different functional properties